NASDAQ · OABITechnologyR&D — Physical & Biological Sciences

OmniAb financials

$4.740.00%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
Revenue$18.7M$26.4M$34.2M$59.1M
Gross profit$18.4M$26.4M$34.2M$59.1M
Gross margin98.4%100.0%100.0%100.0%
Operating income-$71.5M-$76.9M-$69.6M-$26.6M
Net income-$64.8M-$62.0M-$50.6M-$22.3M
Net margin−347.0%−235.1%−148.2%−37.8%
Diluted EPS$-0.57$-0.61$-0.51$-0.26
EBITDA-$49.8M-$53.3M-$49.9M-$8.4M
Operating cash flow-$36.5M-$39.7M$2.3M-$3.0M
Free cash flow-$37.0M-$41.5M$703.0K-$20.2M
Diluted shares113.6M102.4M99.7M85.3M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31
Cash & equivalents$25.5M$27.6M$16.4M$33.4M
Short-term investments$28.5M$31.8M$70.6M$54.9M
Total debt$0.00$0.00$0.00$0.00
Total assets$300.9M$325.6M$375.2M$421.2M
Total liabilities$33.9M$37.9M$60.6M$79.8M
Shareholders' equity$267.0M$287.6M$314.6M$341.4M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology